


GeneQuantum Healthcare, MITRO Biotech to develop Radionuclide Conjugates

04 February 2019 | News | By Sonali Wankhade

GeneQuantum has been committed to building a differentiated innovation platform to solve the key challenges of the biopharmaceutical industry



GeneQuantum Healthcare of Suzhou and MITRO Biotech of Nanjing recently signed the "Strategic Cooperation Agreement on Next Generation Radionuclide Conjugates Development" in Nanjing. Dr. Gang Qin, President of GeneQuantum and Dr. Xinping Li, CEO of MITRO, attended the signing ceremony with their teams.

In pursuit of achieving mutually beneficial win-win cooperation, the two parties intend to integrate the leading bioconjugation platform of GeneQuantum and the unique advantages of MITRO in radiolabeling and molecular imaging technique to jointly develop next generation radionuclide conjugates for rapid and efficient companion diagnosis and precision target therapy on tumors.

"Since its establishment, GeneQuantum has been committed to building a differentiated innovation platform to solve the key challenges of the biopharmaceutical industry. Based on our proprietary ligase dependent conjugation technology (LDC), GeneQuantum has gradually established intelligent automatic conjugation system (iLDC) with concurrent fully integrated manufacturing process; combined with our comprehensive quality system which meets global standard, GeneQuantum can provide a holistic solution for the efficient development and manufacturing of any kinds of site-specific bioconjugates. MITRO, on the other hand, has a unique radionuclide production and labeling technology platform," said Dr. Gang Qin.